MC

487.35

-0.5%↓

SANES

7.22

+1.62%↑

ALV

343.8

+0.73%↑

BNP

76.55

-0.05%↓

BBVA

13.235

+1.81%↑

MC

487.35

-0.5%↓

SANES

7.22

+1.62%↑

ALV

343.8

+0.73%↑

BNP

76.55

-0.05%↓

BBVA

13.235

+1.81%↑

MC

487.35

-0.5%↓

SANES

7.22

+1.62%↑

ALV

343.8

+0.73%↑

BNP

76.55

-0.05%↓

BBVA

13.235

+1.81%↑

MC

487.35

-0.5%↓

SANES

7.22

+1.62%↑

ALV

343.8

+0.73%↑

BNP

76.55

-0.05%↓

BBVA

13.235

+1.81%↑

MC

487.35

-0.5%↓

SANES

7.22

+1.62%↑

ALV

343.8

+0.73%↑

BNP

76.55

-0.05%↓

BBVA

13.235

+1.81%↑

Search

AB Science SA

Closed

1.446 7.59

Overview

Share price change

24h

Current

Min

1.324

Max

1.476

Key metrics

By Trading Economics

Income

-3.4M

Sales

512K

Profit margin

-656.641

Employees

28

EBITDA

-1.9M

Dividends

By Dow Jones

Next Earnings

29 Sept 2025

Market Stats

By TradingEconomics

Market Cap

87M

Previous open

-6.14

Previous close

1.446

Technical Score

By Trading Central

Confidence

Bearish Evidence

AB Science SA Chart

Past performance is not a reliable indicator of future results.

Related News

3 Jul 2025, 23:45 UTC

Acquisitions, Mergers, Takeovers

Orix Corp. USA to Buy Majority Stake in Hilco Global >8591.TO

3 Jul 2025, 23:42 UTC

Market Talk

Gold Edges Higher Amid U.S. Fiscal-Deficit Concerns -- Market Talk

3 Jul 2025, 23:41 UTC

Market Talk

Nikkei May Rise After Solid U.S. Jobs Data -- Market Talk

3 Jul 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 Jul 2025, 23:15 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Beach Energy Could Smooth Path to Santos Takeover Approval -- Market Talk

3 Jul 2025, 22:59 UTC

Market Talk

Uranium Market About to Enter Lull -- Market Talk

3 Jul 2025, 22:58 UTC

Market Talk

Value Emerging in Diversified Miners Despite Headwinds -- Market Talk

3 Jul 2025, 22:47 UTC

Market Talk

Australian Household Spending Numbers Key Ahead of RBA Meeting -- Market Talk

3 Jul 2025, 22:21 UTC

Earnings

This Summer's Big TV Hit Brings Back Soap Opera Memories -- Barrons.com

3 Jul 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3 Jul 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 Jul 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

3 Jul 2025, 20:41 UTC

Market Talk

KKR Seen As Benefiting From Stabilizing Markets -- Market Talk

3 Jul 2025, 20:41 UTC

Market Talk

Global Equities Roundup: Market Talk

3 Jul 2025, 19:28 UTC

Market Talk

Oil Gives Back Some Gains With OPEC+ in View -- Market Talk

3 Jul 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Retreats Ahead of Long Weekend -- Market Talk

3 Jul 2025, 18:34 UTC

Market Talk

Gold Has Winning Week, But Down Day -- Market Talk

3 Jul 2025, 18:18 UTC

Market Talk

Anticipation for Trump Address Gives Grain Traders Optimism -- Market Talk

3 Jul 2025, 18:06 UTC

Market Talk

Global Equities Roundup: Market Talk

3 Jul 2025, 18:06 UTC

Market Talk

Brazilian Stocks, Bonds Expected to Benefit From Benign Macro Trends -- Market Talk

3 Jul 2025, 17:27 UTC

Market Talk

U.S. Oil Rig Count Continues to Slide -- Market Talk

3 Jul 2025, 16:55 UTC

Earnings

Travel Stocks Could Offer Investors a Glorious -2-

3 Jul 2025, 16:55 UTC

Earnings

Travel Stocks Could Offer Investors a Glorious Trip, This Analyst Says -- Barrons.com

3 Jul 2025, 16:20 UTC

Market Talk

Correction to Health Care Roundup: Market Talk

3 Jul 2025, 16:15 UTC

Market Talk

Oil Futures Lose Ground in Choppy Pre-Holiday Trade -- Market Talk

3 Jul 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 Jul 2025, 16:05 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 Jul 2025, 16:05 UTC

Market Talk

Gold Futures Fall Following Jobs Report -- Market Talk

3 Jul 2025, 15:47 UTC

Earnings

Honeywell Stock Is on a Roll. It Looks Ready to Break Out. -- Barrons.com

3 Jul 2025, 15:36 UTC

Earnings
Acquisitions, Mergers, Takeovers

Why It's Time to Buy This Rocks and Cement Spinoff Stock You've Probably Never Heard Of -- Barrons.com

Peer Comparison

Price change

AB Science SA Forecast

Technical Score

By Trading Central

1.426 / 1.448Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.